135 related articles for article (PubMed ID: 3830219)
1. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
Wander HE; Blossey HC; Nagel GA
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1371-4. PubMed ID: 3830219
[TBL] [Abstract][Full Text] [Related]
2. Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status.
Bezwoda WR; Dansey RD; Hesdorffer CS; Browde S
S Afr Med J; 1987 Jul; 72(2):107-9. PubMed ID: 3616780
[TBL] [Abstract][Full Text] [Related]
3. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
Lien EA; Johannessen DC; Aakvaag A; Lønning PE
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):541-3. PubMed ID: 1532904
[TBL] [Abstract][Full Text] [Related]
4. [The use of aminoglutethimide in the treatment of metastatic breast cancer].
Bellora MG; Ciancio A; Ferrero A; Bergamino T; Zola P; Sismondi P
Minerva Ginecol; 1991 Dec; 43(12):589-93. PubMed ID: 1819778
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
[TBL] [Abstract][Full Text] [Related]
6. Aminoglutethimide in advanced breast cancer.
Ceci G; Passalacqua R; Bisagni G; Bella M; Cocconi G
Tumori; 1985 Oct; 71(5):483-9. PubMed ID: 2865833
[TBL] [Abstract][Full Text] [Related]
7. Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
Ferrari V; Zaniboni A; Simoncini E; Marpicati E; Montini E; Moretti R; Marini G
Chemioterapia; 1988 Dec; 7(6):414-9. PubMed ID: 3146444
[TBL] [Abstract][Full Text] [Related]
8. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Wander HE; Nagel GA; Blossey HC; Kleeberg U
Cancer; 1986 Nov; 58(9):1985-9. PubMed ID: 2944573
[TBL] [Abstract][Full Text] [Related]
9. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
[TBL] [Abstract][Full Text] [Related]
10. [Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Wander HE; Teichmann AT; Cremer P; Wieland H; Kruse B; Nagel GA; Kuhn W; Seidel D
Onkologie; 1985 Apr; 8(2):88-92. PubMed ID: 3158861
[TBL] [Abstract][Full Text] [Related]
11. Aminoglutethimide in the treatment of metastatic breast cancer.
Troner MB
Cancer Res; 1982 Aug; 42(8 Suppl):3402s-3404s. PubMed ID: 7083206
[TBL] [Abstract][Full Text] [Related]
12. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy.
Lawrence BV; Lipton A; Harvey HA; Santen RJ; Wells SA; Cox CE; White DS; Smart EK
Cancer; 1980 Feb; 45(4):786-91. PubMed ID: 7357495
[TBL] [Abstract][Full Text] [Related]
13. Aminoglutethimide for the treatment of advanced postmenopausal breast cancer.
Harris AL; Powles TJ; Smith IE; Coombes RC; Ford HT; Gazet JC; Harmer CL; Morgan M; White H; Parsons CA; McKinna JA
Eur J Cancer Clin Oncol; 1983 Jan; 19(1):11-17. PubMed ID: 6682769
[TBL] [Abstract][Full Text] [Related]
14. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC
Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
[TBL] [Abstract][Full Text] [Related]
15. Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments.
Zambetti M; Brambilla C; Tancini G; Bonadonna G
Tumori; 1987 Aug; 73(4):369-73. PubMed ID: 3660475
[TBL] [Abstract][Full Text] [Related]
16. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Bruning PF; Bonfrer JM; Hart AA; van der Linden E; de Jong-Bakker M; Moolenaar AJ; Nooijen WJ
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989
[TBL] [Abstract][Full Text] [Related]
17. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
18. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
19. [Aminoglutethimide therapy in advanced breast cancer].
Kühböck J; Ludwig H; Pötzi P; Zielinski C
Wien Med Wochenschr; 1985 Dec; 135(23-24):608-11. PubMed ID: 4096007
[TBL] [Abstract][Full Text] [Related]
20. Ablative procedures in patients with metastatic breast carcinoma.
Wells SA; Santen RJ
Cancer; 1984 Feb; 53(3 Suppl):762-5. PubMed ID: 6362827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
